Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eprx.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Eupraxia Pharmaceuticals Inc. (EPRX.TO) measures how much investors pay for each dollar of the company's trailing earnings. EPRX.TO's current PE ratio of N/A is calculated by dividing its stock price of $8.33 by its TTM earnings per share of -$0.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc.You EPRX.TO | $299M | N/A | — | -$0.74 |
 Cybin Inc. CYBN.NE | $138M | N/A | — | -$0.61 |
 Medical Facilities Corporation DR.TO | $325M | 10.68x | — | $1.08 |
 Fennec Pharmaceuticals Inc. FRX.TO | $364M | N/A | — | -$0.36 |
 Helix BioPharma Corp. HBP.TO | $121M | N/A | — | -$0.09 |
 Medicenna Therapeutics Corp. MDNA.TO | $31M | N/A | — | -$0.15 |
 NervGen Pharma Corp. NGEN.V | $408M | N/A | — | -$0.60 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.98 | — | |
2024-12-31 FY2024 | — | $-0.72 | — | |
2023-12-31 FY2023 | — | $-1.17 | — | |
2022-12-31 FY2022 | — | $-1.21 | — | |
2021-12-31 FY2021 | — | $-1.61 | — | |
2020-12-31 FY2020 | — | $-0.31 | — | |
2019-12-31 FY2019 | — | $-0.56 | — | |
2018-12-31 FY2018 | — | $-1.03 | — | |
2017-12-31 FY2017 | — | $-0.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Eupraxia Pharmaceuticals Inc. (EPRX.TO) measures how much investors pay for each dollar of the company's trailing earnings. EPRX.TO's current PE ratio of N/A is calculated by dividing its stock price of $8.33 by its TTM earnings per share of -$0.74.
Frequently asked questions
EPRX.TO pe ratio · 6 questionsEPRX.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.33 and TTM EPS of -$0.74. Data sourced from Financial Modeling Prep via EPRX.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08